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We describe here successful designs of strong inhibitors for porcine pancreatic elastase (PPE) and
Streptomyces griseus protease B (SGPB). For each enzyme two inhibitor variants were designed. In
one, the reactive site residue (position 18) was retained and the best residues were substituted at
contact positions 13, 14, and 15. In the other variant the best residues were substituted at all contact
positions except the reactive site where a Gly was substituted. The four designed variants were: for
PPE, T13E14Y15-OMTKY3 and T13E14Y15G18M21P32V36-OMTKY3, and for SGPB, S13D14Y15-OMTKY3 and
S13D14Y15G18I19K21-OMTKY3. The free energies of association (DG0) of expressed variants have been
measured with the proteases for which they were designed as well as with ﬁve other serine prote-
ases and the results are discussed.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Standard mechanism serine protease inhibitors bind to serine
proteases like substrates but instead of getting hydrolyzed theyform a stable non-covalent complex with the serine protease [1–
4]. Based on sequence homologies and disulﬁde bond topologies,
eighteen families of standard mechanism serine protease inhibi-
tors have been recognized [3,5]. Despite differences in sequences,
size, and disulﬁde bonding patterns, all of the eighteen families
follow the same mechanism of inhibition commonly called the
standard mechanism of inhibition [1].
We have been involved in the research work aimed at develop-
ing a sequence to reactivity algorithm (SRA) for the Kazal family of
standard mechanism inhibitors. In the ﬁrst part of our research
project, ovomucoid third domains (a Kazal family inhibitor) were
prepared and puriﬁed from egg whites of a large number of species
of birds. The ovomucoid third domains were sequenced [6–8] and
free energy changes of their association (DG0) were measured with
a panel of six serine proteases [9–12]. In the second part of the pro-
ject all single amino acid variants at ten of the twelve consensus
contact positions of turkey ovomucoid third domain (OMTKY3)
(see Fig. 1) were prepared and their DG0 values were measured
against the same set of six serine proteases [13–15]. The culmina-
tion of these two projects produced an SRA for the Kazal family of
inhibitors, in addition to providing a large and unbiased set of
inhibitors for testing the algorithm.
Fig. 1. Primary structure of expressed wtOMTKY3. The ﬁrst ﬁve residues are not
shown because they are not part of the expressed OMTKY3 (and its variants) and
have been found to have no effect on the inhibitory activity of OMTKY3. The
residues are numbered sequentially as well as in Schechter–Berger notation [30]. In
Schechter–Berger notation, the reactive site residue (shown by the arrow) is labeled
as P1. Residues towards the N-terminal of the P1 residue are sequentially labeled as
P2, P3, . . ., Pn whereas residues C-terminal to P1 residue are labeled as P10 , P20 , . . .,
Pn0 . The amino acids shown as ﬁlled circles are the consensus contact residues in
inhibitor–protease complexes. The two ﬁlled circles shown in grey color represent
the residues which in addition to being the contact residues also play a structural
role.
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tivity of DG0 values when substitutions at the contact positions of
OMTKY3 are made. In principle, a substitution at an inhibitor con-
tact position is additive if that position is independent of other
positions in the inhibitor and it also does not produce alterations
through protease contact residues [16,17]. Thus, the additivity de-
pends both on the contact position of the inhibitor as well as on the
serine protease being investigated. We presented extensive (400)
additivity tests in our SRA paper [15]. These tests were based on
natural ovomucoid third domains that differed from OMTKY3 at
two or more contact positions [6,14]. Since that time we have per-
formed many more additivity tests [18]. The general consensus in
all additivity tests is that most contact positions, with the excep-
tion of the contact positions P2 and P01, are additive with the six ser-
ine proteases that we have used [15,16,19,20]. The two important
applications of additivity-based SRA are: (i) the prediction, with
few restrictions, of the free energy of association of any Kazal
inhibitor of known protein or gene sequence with any of the six
serine proteases we have used, and (ii) the design of strong, spe-
ciﬁc, or non-speciﬁc inhibitors for the six serine proteases.
Structure based design of strong and speciﬁc drugs and ligands
for target proteins is an area of great academic and practical inter-
est [21–23]. In this communication, we describe the design and
expression of the strongest possible OMTKY3-based inhibitors for
PPE and SGPB. We also measure the free energy changes in the
association of the designed inhibitors with the target serine prote-
ase as well as with the other ﬁve serine proteases in the panel and
compare them with the predicted free energy changes. The pre-
dicted free energy changes of association of the strongest possible
inhibitors were outside our reliable measurement range
(4.0–17.5 kcal/mol). Therefore, to bring these numbers into the
measureable range we introduced a Gly at the P1 position of
the designed inhibitor instead of the best residue dictated by theSRA. The substitution of Gly at P1 is based on overwhelming data
[14,24–27] that show strong additivity of substitutions involving
the P1 position of inhibitors as well as substrates. Most of the pre-
dicted and the measured values were in excellent agreement. The
success of these studies emphasizes the importance of including
more serine proteases in further developing the sequence to reac-
tivity algorithm.
2. Materials and methods
2.1. Chemicals
Four of the six serine proteases used in this research namely,
TLCK treated bovine a-chymotrypsin (Worthington), human leuko-
cyte elastase (HLE) (Elastin Products), porcine pancreatic elastase
(PPE) (Sigma), and subtilisin Carlsberg (CARL) (Sigma) were ob-
tained from the commercial sources listed in parentheses. The
other two serine proteases, Streptomyces griseus protease A and B,
(SGPA and SGPB) were puriﬁed from a commercially obtained
preparation of pronase (Sigma) as described [28]. The identity
and the purity of the two proteases were established by amino acid
analysis and by analytical ion exchange chromatography.
The chromogenic and ﬂuorogenic synthetic substrates of the
type succinyl-ala-ala-pro-Xxx-pNA and succinyl-ala-ala-pro-Xxx-
AMC were purchased from BACHEM. Other chemicals used in this
work were all analytical grade.2.2. Construction and expression of variants
Site-directed mutagenesis was carried out to introduce amino
acid substitutions in the recombinant OMTKY3. For the variant
S13D14Y15, the plasmid of variant Y15 was used as template, and
the following primers were used to create the indicated changes:
S13D14Y15-forward primer: 50-GAC TGT AGT GAG TAC CCT AGC
GAT TAC TGC ACG CTG-30; S13D14Y15-reverse primer: 50-CAG CGT
GCA GTA ATC GCT AGG GTA CTC ACT ACA GTC-30. The variant
plasmid could be easily distinguished from the parental plasmid
by the digestion with Pst I. For the mutant S13D14Y15G18I19K21,
the plasmid of the variant S13D14Y15 was further used as template,
and the following primers were used: S13D14Y15G18I19K21-forward
primer: 50-C TGC ACG GGG ATC TAC AAA CCT CTC TGT GGA
TC-30; S13D14Y15G18I19K21-reverse primer: 50-GA TCC ACA GAG
AGG TTT GTA GAT CCC CGT GCA G-30.
For the variant T13E14Y15, the plasmid of variant Y15 was used as
template, and the following primers were used to create the indi-
cated changes: T13E14Y15-forward primer: 50-GAC TGT AGT GAG
TAC CCT ACG GAG TAT TGC ACG CTG-30; T13E14Y15-reverse primer:
50-CAG CGT GCA ATA CTC CGT AGG GTA CTC ACT ACA GTC-30. The
variant plasmid could also be easily distinguished from the
parental plasmid by the digestion with Pst I. For the variant
T13E14Y15G18M21, the plasmid of the variant T13E14Y15 was further
used as template, and the following primers were used: T13E14
Y15G18M21-forward primer: 50-G TAT TGC ACG GGG GAA TAC
ATG CCT CTC TG-30; T13E14Y15G18M21-reverse primer: 50-CA GAG
AGG CAT GTA TTC CCC CGT GCA ATA C-30. For the variant T13E14
Y15G18M21P32V36, the plasmid of the variant T13E14Y15G18M21 was
further used as template, and the following primers were used:
T13E14Y15G18M21 P32V36-forward primer: 50-CA TAT CCA AAC AAG
TGC GTC TTC TGC AAT G-30; T13E14Y15G18M21 P32V36-reverse
primer: 50-C ATT GCA GAA GAC GCA CTT GTT TGG ATA TG-30.
All the substitutions were conﬁrmed by DNA sequencing. Each
variant plasmid was then transformed into Escherichia coli strain
RV308 for protein expression. An engineered Z domain of protein
A was used as a fusion protein in the construction of variant
plasmids [14]. The expressed protein inhibitors were puriﬁed by
Table 1
Free energy changes of inhibitor–protease association. Standard free energy changes
for the association of some OMTKY3 single variants with six serine proteases at pH 8.3
and 22 ± 1 C.
OMTKY3 variants CHYM HLE PPE SGPA SGPB CARL
DG0 (kcal/mol)
wtOMTKY3 15.23 13.21 14.34 15.49 14.51 14.22
S13OMTKY3 15.65 12.75 14.18 17.31 17.07 14.52
T13OMTKY3 14.85 13.04 14.43 17.30 16.44 13.34
D14OMTKY3 16.07 13.70 14.96 16.02 15.53 16.71
E14OMTKY3 15.94 14.62 15.05 16.12 15.13 16.44
Y15OMTKY3 16.09 13.39 15.41 16.82 16.14 15.05
G18OMTKY3 15.96 9.91 12.09 10.33 9.56 11.89
I19OMTKY3 12.61 12.49 12.15 15.26 15.13 13.49
K21OMTKY3 14.57 12.61 13.61 15.16 14.78 14.31
M21OMTKY3 12.64 13.96 14.84 15.57 14.38 13.78
P32OMTKY3 14.91 12.95 15.28 14.47 13.43 13.15
V36OMTKY3 15.19 12.87 15.19 16.51 14.65 13.56
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After afﬁnity separation the fusion protein was cleaved at an engi-
neered methionine placed at the junction of the Z domain and the
ovomucoid third domain variant. The inhibitor variants were then
separated from cleaved fusion protein by size exclusion column
chromatography on Bio-gel P-10 column and puriﬁed by ion ex-
change column chromatographies on SP-sepharose and Q-sephar-
ose columns. The variants were characterized by size exclusion
HPLC, amino acid analysis, and by mass spectral analysis by MALDI
TOF.
2.3. Measurement of free energy changes in the association of
inhibitors with proteases
The free energy changes in the association of the inhibitors with
the panel of six serine proteases were calculated from experimen-
tally determined values of association equilibrium constants, Ka, by
using the equation, DG0 = RT lnKa. Association equilibrium con-
stants for the binding of the inhibitor variants with the serine pro-
teases were determined by a procedure perfected in this lab [9,14].
The Ka measurements, except in those cases where they were ex-
pected to be >1013M1, were performed in 0.1 M Tris–HCl buf-
fer + 0.02 M CaCl2 + 0.005% Triton X-100, pH 8.3. The technical
difﬁculties such as long incubation times (several weeks) and
non-availability of sensitive enough substrates to accurately deter-
mine picomolar concentrations of the protease used in these mea-
surements, prevent us from measuring large Ka values (>1013 M1)
at pH 8.3. However, we have found that the Ka measurement range
can be increased by about a factor of 10 for some enzymes (such as
SGPA, SGPB and chymotrypsin) by performing the Ka measure-
ments at pH 5.0 and then converting these values to pH 8.3 by
using an appropriate conversion factor. As part of our studies on
pH-dependencies of Ka, we measured Ka values of a number of P1
variants of OMTKY3 with different serine proteases in the pH range
4.0–10.0. The pH dependence for variants having non-ionizable
amino acid residues at P1 was found to be identical, within exper-
imental error, for a given protease ([29] and Qasim and Laskowski
– unpublished). This means that the ratio of Ka for P1L variant (or
any other non-ionizable P1 variant) at pH 8.3 and at any given
pH is constant. Such a ratio at pH 8.3 and pH 5.0 comes out to be
115 for SGPB. This factor can be used for estimating Ka value at
pH 8.3 from a measured Ka at pH 5.0. This method works well
for measurements in which the Ka value is P1013 M1. Such mea-
surements are more easily done at pH 5.0 because the drop in Ka
with pH is steeper than the drop in the enzyme activity. The Ka
measurements at pH 5.0 were performed in 0.1 M acetic acid–ace-
tate buffer + 0.02 M CaCl2 + 0.005% Triton X-100, pH 5.0.3. Results and discussion
3.1. DG0 values of inhibitor variants
The amino acid sequence of recombinant wild type OMTKY3 is
shown in Fig. 1. The consensus contact residues of OMTKY3 deter-
mined from the X-ray crystallographic structures of its complexes
with different serine proteases are shown as ﬁlled circles. There are
12 such contact residues in OMTKY3. Our lab, in collaboration with
Anderson’s lab at Rutgers, constructed and expressed all single
amino acid variants at ten of the twelve contact positions shown
in Fig. 1. The two contact positions which were not subjected to
substitution are Cys16 (P3) and Asn33 (P150). These residues, in addi-
tion to being contact residues, also serve as structural residues and
their mutation generally produces dramatic changes in the confor-
mation and stability of OMTKY3. In all, 190 inhibitor variants
(corresponding to single amino acid changes at 10 contact posi-
tions) and the wild type OMTKY3 were expressed, puriﬁed, and
the DG0 values for the interaction of these variants with six serine
proteases were measured [15]. The DG0 values of some of the
variants that are relevant to the research work described in this
paper are listed in Table 1.3.2. Design of the strongest possible inhibitors for PPE and SGPB
The strongest OMTKY3-based inhibitor for PPE and SGPB will be
the one that has a residue at each of the contact positions that pro-
duces the highest association equilibrium constant for these prote-
ases. The sequences of the strongest possible inhibitors for all six
serine proteases have been described [15]. For PPE and SGPB, these
sequences are: T13E14Y15M21P32V36 and S13D14Y15I19K21, respec-
tively. Here, only the residues that are different from wtOMTKY3
(Fig. 1) are shown. Assuming full additivity at each contact position
one can calculate the free energy change (DG0predicted) in the asso-
ciation of these variants with any of the six serine proteases by
using the following relation [15]:
DG0predicted ¼ DG0TKY3 þ RDDG0ðXTKY3iX0Þ ð1Þ
The term DDG0 (XTKY3 i X0) represents the change in the free en-
ergy of association when a contact residue in OMTKY3, X, at posi-
tion i is changed to X0. The summation extends to all contact
positions. The free energies of association of OMTKY3 and single
variants used for the design of these inhibitors are shown for all
six enzymes in Table 1. If the above equation is used to calculate
free energy of association for the two inhibitors that are designed
for PPE and SGPB, their predicted free energies of association will
come out to be 18.5 kcal/mol (Ka = 5.1  1013 M1) for inhibitor
sequence T13E14Y15M21P32V36 (for PPE) and 20.6 kcal/mol
(Ka = 1.8  1015 M1) for S13D14Y15I19K21 (for SGPB). Our range of
accurate DG0 determinations ranges from 4.0 kcal/mol to
17.5 kcal/mol (Ka: 103 M1 to 1013 M1). These numbers, however,
represent the lower and the upper limit of our measurements
when all six serine proteases are considered. For individual en-
zymes these ranges are slightly different. For example, for PPE
the upper limit is 16.2 kcal/mol, whereas for SGPB it is 17.5 kcal/
mol. We were able to extend the upper limit of DG0 value for SGPB
to 18.9 kcal/mol (a 10-fold increase in Ka) by determining DG0 at
pH 5.0 and converting it to the DG0 at pH 8.3 by using our knowl-
edge of pH dependence of DG0. The predicted DG0 values for the
strongest possible inhibitor of PPE and SGPB are clearly outside
our measurement range. Therefore, although we could make the
strongest inhibitors using the above sequences, we would not be
able to measure them in order to see whether they are actually
as strong as our predictions suggest. In order to overcome this
3024 M.A. Qasim et al. / FEBS Letters 587 (2013) 3021–3026problem, we made the strongest inhibitors in which the best P1
residue was replaced by the simplest of the amino acids, i.e. Gly.
The choice of P1 and the choice of the amino acid Gly for substitu-
tion in the designed inhibitor were made on the basis of clear mer-
its. The P1 is the most additive of all of the contact residues. The
data on the additivity of the P1 position are overwhelming
[3,5,24–27]. The choice of Gly at P1 is based on the simplicity of
this amino acid (no side chain) and its uniformly lower DG0 value
for all serine proteases.
3.3. Strongest inhibitors with a Gly at P1
The design strategy for these inhibitors was exactly the same as
described above except that the best amino acid residue at P1 was
replaced by a Gly. The two designed inhibitors are designated as
T13E14Y15G18M21P32V36-OMTKY3 and S13D14Y15G18I19K21-OMTKY3.
For each of these designed inhibitors, we also produced an inter-
mediate designed inhibitor (see Tables 2 and 3) that had the best
residues at P6, P5, and P4 positions but having the rest of the con-
tact residues left the same as in wtOMTKY3. Having inhibitors with
fewer substitutions is important particularly in situations where
the measured DG0 values for the designed inhibitor do not match
with the predicted DG0 values. The measured and predicted Kas
and the free energies of association of designed inhibitors for PPE
and SGPB are given in Tables 2 and 3. The DG0 values shown in Ta-
bles 2 and 3 are at pH 8.3. With the exception of T13E14Y15 and
S13D14Y15 values for SGPA and SGPB all other values were directly
measured at pH 8.3. The DG0 values for T13E14Y15 and S13D14Y15 for
SGPA and SGPB were measured at pH 5.0 and converted toDG0 val-
ues at pH 8.3 by using the extensive DG0 data that we have ac-
quired at both of these pH values. A cursory look at the
measured and predicted DG0 values shows that most of these are
close to each other. The question, how close the measured and
the predicted DG0 values should be to each other, in order to be
considered within experimental error, was addressed in detail
in our SRA paper [15]. The difference in the predicted free energyTable 2
Equilibrium constants and free energies of association for the designed inhibitors. Assoc
designed for PPE. The values listed here are at pH 8.3 and 22 ± 1 C. Predicted values wer
OMTKY3 variants CHYM HLE
Ka (M
1)
T13E14Y15 Measured 9.4  1011 2.2  1010
Predicted 1.5  1012 7.0  1010
T13E14Y15G18M21P32V36 Measured 9.2  106 3.1  108
Predicted 3.4  105 3.2  108
DG0 (kcal/mol)
T13E14Y15 Measured 16.16 13.96
Predicted 16.44 14.64
T13E14Y15G18M21P32V36 Measured 9.40 11.46
Predicted 7.47 11.48
Table 3
Equilibrium constants and free energies of association for the designed inhibitors. Assoc
designed for SGPB. The values listed here are at pH 8.3 and 22 ± 1 C. Predicted values we
OMTKY3 variants CHYM HLE
Ka (M
1)
S13D14Y15 Measured 1.1  1012 7.6  109
Predicted 7.2  1012 8.7  109
S13D14Y15G18I19K21 Measured 9.0  105 6.8  106
Predicted 9.4  105 3.4  106
DG0 (kcal/mol)
S13D14Y15 Measured 16.26 13.34
Predicted 17.36 13.42
S13D14Y15G18I19K21 Measured 8.04 9.22
Predicted 8.06 8.82of association and the measured free energy of association
(DG0predicted  DG0measured) is represented as DG0I (see Eq. (2)).
The term DG0I is in effect the sum of any non-additivity and any
experimental error inherent in the acquisition of the data set that
is used as the predictive tool. The error in the measurement of DG0
value for OMTKY3 for all six enzymes is ±100 cal/mol. The error is
generally higher at the lower and the upper ends of our measure-
ment range. Thus, in our overall calculation of error, we use a
2r level to decide whether the DG0I is due to experimental error
or whether it should be attributed to non-additivity. For details
of error analysis, readers are referred to our SRA paper [15]. The
calculation of DG0I is performed by using the following equation:
DG0I experimental ¼ 2r
ﬃﬃﬃﬃﬃ
k2
q
 kþ 2 ¼ 200cal=mol
ﬃﬃﬃﬃﬃ
k2
q
 kþ 2 ð2Þ
Here, k represents the number of amino acid changes from
OMTKY3 sequence. The DG0I value for three changes comes out
to be 0.57 kcal/mol and for six and seven changes 1.13 kcal/mol
and 1.33 kcal/mol, respectively. According to this criterion, 17 of
the 24 (71%) DG0 values are in good to excellent agreement with
the predicted DG0 values (see Tables 2 and 3). This is slightly better
than the value of 63% found for the much larger set of 400 compar-
isons [15]. Of the seven measured values that do not agree with the
predicted values, the one for S13D14Y15G18I19K21-OMTKY3 for SGPB
is only marginally outside the allowed error range. For the other six
a combination of different factors may be responsible for the dis-
agreement. It is worthwhile to mention here that of the six en-
zymes we use, the two most non-additive enzymes are HLE and
CARL [15,31]. Three of the six predominantly non-additive num-
bers reported here are for HLE and CARL. The structural explana-
tion for the greater non-additivity in CARL has been provided by
the X-ray crystallographic structure determination of the OMT-
KY3–CARL complex [32]. On the other hand, the greater degree
of non-additivity in HLE is at least in part due to inherent difﬁcul-
ties in accurate determinations of DG0 for this protease. In spite ofiation equilibrium constants and free energies of associations of the two inhibitors
e calculated using the data given in Table 1 as described in the text.
PPE SGPA SGPB CARL
6.8  1011 1.4  1014 3.8  1013 1.5  1011
1.0  1012 1.8  1014 6.9  1013 1.4  1012
3.0  1011 3.1  1010 2.5  109 5.8  108
1.1  1012 3.0  1010 2.8  109 6.4  108
15.97 19.10 18.33 15.09
16.20 19.24 18.68 16.40
15.49 14.16 12.69 11.83
16.26 14.14 12.75 11.89
iation equilibrium constants and free energies of associations of the two inhibitors
re calculated using the data given in Table 1 as described in the text.
PPE SGPA SGPB CARL
5.3  1011 9.2  1013 6.1  1013 8.9  1011
5.7  1011 1.6  1014 1.6  1014 1.7  1013
1.4  108 4.6  109 4.8  1010 7.8  109
8.3  107 8.9  109 3.9  1011 1.1  1011
15.82 18.85 18.61 16.13
15.87 19.18 19.18 17.86
11.00 13.04 14.41 13.40
10.69 13.43 15.65 14.91
M.A. Qasim et al. / FEBS Letters 587 (2013) 3021–3026 3025some failures, the results in general are highly encouraging. First,
despite six and seven changes in the contact position of designed
inhibitors, the additivity works very well. Second, the measured
DG0 values for the designed inhibitors against the proteases for
which they were designed were reasonably good. Third, quite
astonishingly the designed strongest inhibitor for SGPB has signif-
icantly higher DG0 value for SGPB than that for SGPA. The two en-
zymes are sequentially and structurally very closely related
[33,34]. Enzymatically SGPA is more active [35] and also is inhib-
ited about 2- to 20-fold more strongly by most of the naturally
occurring inhibitors that we have tested in our lab. The fact that
the S13D14Y15G18I19K21 OMTKY3 inhibits SGPB 10 times more
strongly than SGPA is important and suggests that our SRA can
be used for the design of speciﬁc inhibitors for closely related ser-
ine proteases.
The ﬁndings of the increasing roles of serine proteases in cancer
[36], in inﬂammations [37], and in many viral infections [38]
makes them an important target for the design of strong and spe-
ciﬁc inhibitors. Such designed inhibitors can be used as molecular
tools in the investigation of the structure and properties of target
serine proteases as well as can also be used as therapeutics. SRAs
similar to the one developed for the six serine proteases and used
here can in principle also be developed for other serine proteases
using our OMTKY3 variant set and can then be used for inhibitor
design against them.
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